Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Manipulation of Glucose and Hydroperoxide Metabolism to Improve Radiation Response.

Floberg JM, Schwarz JK.

Semin Radiat Oncol. 2019 Jan;29(1):33-41. doi: 10.1016/j.semradonc.2018.10.007. Review.

2.

Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging.

Floberg JM, DeWees TA, Chin RI, Garsa AA, Dehdashti F, Nussenbaum B, Oppelt PJ, Adkins DR, Gay HA, Thorstad WL.

Head Neck. 2018 Oct;40(10):2280-2287. doi: 10.1002/hed.25337. Epub 2018 Jul 26.

PMID:
30051553
3.

Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer.

Floberg JM, Fowler KJ, Fuser D, DeWees TA, Dehdashti F, Siegel BA, Wahl RL, Schwarz JK, Grigsby PW.

EJNMMI Res. 2018 Jun 15;8(1):52. doi: 10.1186/s13550-018-0403-7.

4.

Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.

Rashmi R, Huang X, Floberg JM, Elhammali AE, McCormick ML, Patti GJ, Spitz DR, Schwarz JK.

Cancer Res. 2018 Mar 15;78(6):1392-1403. doi: 10.1158/0008-5472.CAN-17-2367. Epub 2018 Jan 16.

5.

Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database.

Fischer-Valuck BW, Chen I, Srivastava AJ, Floberg JM, Rao YJ, King AA, Shinohara ET, Perkins SM.

Cancer. 2017 Feb 15;123(4):682-687. doi: 10.1002/cncr.30405. Epub 2016 Nov 2.

6.

The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Ibrahim N, Kusmirek J, Struck AF, Floberg JM, Perlman SB, Gallagher C, Hall LT.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):102-9. eCollection 2016.

7.

Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS.

Sci Transl Med. 2014 Jun 11;6(240):240ra75. doi: 10.1126/scitranslmed.3007646.

9.

(18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Struck AF, Hall LT, Kusmirek JE, Gallagher CL, Floberg JM, Jaskowiak CJ, Perlman SB.

Am J Nucl Med Mol Imaging. 2012;2(4):475-82. Epub 2012 Oct 15.

10.

Impact of expectation-maximization reconstruction iterations on the diagnosis of temporal lobe epilepsy with PET.

Floberg JM, Struck AF, Peters BK, Jaskowiak CJ, Perlman SB, Hall LT.

Am J Nucl Med Mol Imaging. 2012;2(3):335-43. Epub 2012 Jul 10.

11.

Improved kinetic analysis of dynamic PET data with optimized HYPR-LR.

Floberg JM, Mistretta CA, Weichert JP, Hall LT, Holden JE, Christian BT.

Med Phys. 2012 Jun;39(6):3319-31. doi: 10.1118/1.4718669.

12.

Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT.

Grudzinski JJ, Floberg JM, Mudd SR, Jeffery JJ, Peterson ET, Nomura A, Burnette RR, Tomé WA, Weichert JP, Jeraj R.

Phys Med Biol. 2012 Mar 21;57(6):1641-57. doi: 10.1088/0031-9155/57/6/1641. Epub 2012 Mar 7.

13.

Surgical decision making in temporal lobe epilepsy: a comparison of [(18)F]FDG-PET, MRI, and EEG.

Struck AF, Hall LT, Floberg JM, Perlman SB, Dulli DA.

Epilepsy Behav. 2011 Oct;22(2):293-7. doi: 10.1016/j.yebeh.2011.06.022. Epub 2011 Jul 27.

14.

Dynamic PET denoising with HYPR processing.

Christian BT, Vandehey NT, Floberg JM, Mistretta CA.

J Nucl Med. 2010 Jul;51(7):1147-54. doi: 10.2967/jnumed.109.073999. Epub 2010 Jun 16.

Supplemental Content

Loading ...
Support Center